Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.00827

Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting

  • 1University General Hospital Attikon, Greece
  • 2Free University of Brussels, Belgium

Head and neck squamous cell carcinoma (HNSCC) represents a group of tumors arisng in the oral cavity, oropharynx and larynx. Although HNSCC is traditionally associated with tobacco and alcohol consumption, a growing proportion of head and neck tumors, mainly of the oropharynx, are associated with Human Papilloma Virus (HPV). Recurrent/metastatic disease is characterized by dismal prognosis and there is an unmet need for the development of biomarkers for detection of early disease, accurate prediction of prognosis and appropriate selection of therapy. Based on the REMARK guidelines, a variety of diagnostic and prognostic biomarkers are being evaluated in clinical trials but their clinical significance is doubtful. Herein, we will focus on biomarkers in HNSCC used in the clinical setting and we will illustrate their clinical relevance.

Keywords: head and neck cancer, HPV, Tobacco, PET/CT scan, biomarkers, PDL-1, Immunoscore

Received: 17 Jun 2019; Accepted: 12 Aug 2019.

Edited by:

Ingeborg Tinhofer, Charité Medical University of Berlin, Germany

Reviewed by:

Jochen Hess, Heidelberg University, Germany
Thomas Melchardt, Paracelsus Medical University, Austria  

Copyright: © 2019 Economopoulou, Van Gestel, KOTSANTIS and Psyrri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Amanda Psyrri, University General Hospital Attikon, Athens, Greece,